HONG KONG – In an era when data are more valuable than gold, China has rolled out new regulations to strengthen control of its human genetics data. Any foreign biotech companies or institutes intending to use Chinese data must engage a Chinese partner in the research project, among other new requirements.
In an era when data are more valuable than gold, China has rolled out new regulations to strengthen control of its human genetics data. Any foreign biotech companies or institutes intending to use Chinese data must engage a Chinese partner in the research project, amongst other new requirements.
HONG KONG – With operations in the U.S, the Netherlands and China, Shanghai-based biopharma firm Harbour Biomed Therapeutics Ltd. inked a 10-year pact with Erasmus MC from the University Medical Center Rotterdam to grow its footprint in Europe. Both sides will develop biotherapeutics to treat cancer and immunological diseases.
HONG KONG – China has approved its third homegrown PD-1 drug in merely six months, with a nod for camrelizumab, developed by pharma R&D giant Jiangsu Hengrui Medicine Co. Ltd., as a third-line treatment for recurrent or refractory classical Hodgkin lymphoma.
HONG KONG – China-based Hansoh Pharmaceutical Group Co. Ltd. had a strong debut on Hong Kong's stock market and raised $1 billion on June 14 – despite widespread protests and a political crisis here – becoming the biggest health care IPO in Hong Kong this year.
HONG KONG – China has approved its third homegrown PD-1 drug in merely six months, with a nod for camrelizumab, developed by pharma R&D giant Jiangsu Hengrui Medicine Co. Ltd., as a third-line treatment for recurrent or refractory classical Hodgkin's lymphoma.
HONG KONG – China-based Hansoh Pharmaceutical Group Co. Ltd. had a strong debut on Hong Kong's stock market and raised $1 billion on Friday – despite widespread protests and a political crisis here – becoming the biggest health care IPO in Hong Kong this year.
HONG KONG – Suzhou-based Alphamab Oncology Co. Ltd. pocketed $60 million in a series B financing to advance into the clinic with its potentially first-in-class PD-L1/CTLA4 bispecific antibody, KN-046, and to prepare for commercialization of its more advanced product, subcutaneous PD-L1 antibody KN-035 (envafolimab).
HONG KONG – Suzhou-based Alphamab Oncology Co. Ltd. pocketed $60 million in a series B financing to advance into the clinic with its potentially first-in-class PD-L1/CTLA4 bispecific antibody, KN-046, and to prepare for commercialization of its more advanced product, subcutaneous PD-L1 antibody KN-035 (envafolimab).
